Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
Answer from: at Community Practice
Since the reason most folks need biologics is prednisone and considering the side effects, getting patients down to the lowest dose is beneficial.
Sign in or Register to read more
23325
Related Questions
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
What is your approach to de-escalation of asthma inhaler therapy in the setting of negative bronchoprovocation testing when patients are averse to deprescribing.
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?
Do you check blood eosinophil counts in patients with COPD exacerbations to help guide therapy decisions?
What is your approach to the work up and evaluation of loss of asthma control while on a biologic such as dupilumab?
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Are the results of the BOREAS trial generalizable to non-white populations?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?